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S U M M A R Y
Objective: To compare demographic and clinical characteristics, and methicillin-resistant Staphylococcus
aureus (MRSA) strain characteristics, in patients with early-onset (EO) and late-onset (LO) MRSA
nosocomial pneumonia.
Methods: This was a retrospective analysis of data from a multicenter observational study of nosocomial
pneumonia patients admitted between November 2008 and July 2010. Laboratory analyses performed
on MRSA isolates included conﬁrmation of antimicrobial susceptibility and heteroresistance to
vancomycin, USA typing, staphylococcal cassette chromosome (SCC) mec typing, and detection of
Panton–Valentine leukocidin (PVL) genes.
Results: We identiﬁed 134 patients; 42 (31%) had EO MRSA pneumonia and 92 (69%) had LO MRSA
pneumonia. The patients in the LO group were more likely to have risk factors for multidrug-resistant
pathogens (98% vs. 76%, p < 0.001). The MRSA USA300 strain was found with equal frequency in the EO and
LO groups. Likewise, both groups had similar frequencies of isolates exhibiting PVL and SCCmec type IV.
Conclusions: Our ﬁndings provide further evidence of the continued migration of community-associated
MRSA into the healthcare setting in the USA. MRSA USA300 genotype has emerged as a signiﬁcant cause
of LO nosocomial pneumonia in intensive care units. Appropriate anti-MRSA antimicrobial therapy
should be considered for both EO and LO hospital-acquired pneumonia and ventilator-associated
pneumonia.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Nosocomial pneumonia is the second most common hospital-
acquired infection in the USA and is associated with signiﬁcant
morbidity and mortality. Consensus guideline recommendations
suggest the time of onset of pneumonia is an important
epidemiologic variable and a key risk factor for speciﬁc pathogens
and outcomes.1 Early-onset pneumonia (at 4 days of hospitali-
zation) has a better prognosis and is more likely to be caused by§ Presented in part at the 48th Annual Meeting of the Infectious Diseases Society
of America, Vancouver, BC, Canada, October 21–24, 2010 (Abstract 3610), and the
annual International Conference of the American Thoracic Society, Denver,
Colorado, USA, May 13–18, 2011 (Abstract 19213).
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http://dx.doi.org/10.1016/j.ijid.2012.12.013antibiotic-susceptible bacteria, whereas late-onset pneumonia (at
5 days) is more likely to be caused by multidrug-resistant (MDR)
bacteria and is associated with increased morbidity and mortality.1
The unrecognized presence of MDR pathogens in intensive care
unit (ICU) patients with pneumonia can threaten the adequacy of
initial empiric antibiotic therapy and can be associated with an
increase in morbidity and mortality.
Methicillin-resistant Staphylococcus aureus (MRSA) has be-
come one of the most common hospital-acquired pathogens,
accounting for >60% of the clinical S. aureus isolates recovered in
ICUs in the USA.1 Additionally, nosocomial MRSA strains are
generally resistant to several classes of antibiotics and are
therefore difﬁcult and costly to treat. An early study by Pujol
et al. compared methicillin-susceptible Staphylococcus aureus
(MSSA) and MRSA in patients with ventilator-associated pneu-
monia (VAP). MRSA was found to occur exclusively in patientsses. Published by Elsevier Ltd. All rights reserved.
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occurring after 3 days of intubation.2
The worldwide emergence of community-associated MRSA
(CA-MRSA) in the last decade represents a signiﬁcant change in the
epidemiology of MRSA infections. CA-MRSA strains have molecular
characteristics that differ from the traditional healthcare-associ-
ated MRSA (HA-MRSA) strains. In the USA, CA-MRSA strains
typically belong to the pulsed-ﬁeld gel electrophoresis (PFGE) type
USA300, while HA-MRSA strains belong to the USA100 PFGE
proﬁle.3 CA-MRSA strains are associated with carriage of the
Panton–Valentine leukocidin (PVL) gene, a cytotoxin associated
with severe necrotizing infections, including necrotizing skin
lesions as well as necrotizing pneumonia.3,4 CA-MRSA strains also
have microbiologically distinct characteristics including less
antibiotic resistance and lower minimum inhibitory concentra-
tions (MIC) for several antimicrobial agents.3
The recent medical literature indicates that CA-MRSA strains
are being increasingly reported as etiologic agents of nosocomial
infections.5–9 The spread of CA-MRSA into the nosocomial setting
may limit the utility of using epidemiological or clinical risk factors
to assess the likelihood of infection with CA-MRSA vs. HA-MRSA
when making a decision to start empiric antibiotic therapy in
hospitalized patients, thereby threatening the adequacy of the
initial antibiotic selection.
In our institutions, we have recently identiﬁed patients with
nosocomial pneumonia produced by MRSA strains carrying the
PVL gene. We hypothesize that as CA-MRSA clones become more
established in the hospital milieu they will begin to supplant
traditional HA-MRSA strains as causes of late-onset healthcare-
associated infections. To test our hypothesis, we designed a study
with the objective of comparing patient clinical characteristics and
MRSA strain characteristics in patients with early-onset (EO) and
late-onset (LO) MRSA nosocomial pneumonia.
2. Methods
2.1. Study design
This was a retrospective analysis of data collected for the
Improving Medicine through Pathway Assessment of Critical
Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study.
IMPACT-HAP was a multicenter, observational study aimed at
improving the care of ICU patients with nosocomial pneumonia,
including hospital-acquired pneumonia (HAP), VAP, and health-
care-associated pneumonia (HCAP). The study has been described
in detail previously.10 The objective of this analysis was to compare
patient clinical characteristics and MRSA strain characteristics
between patients with EO and LO nosocomial pneumonia caused
by MRSA. Patients with HCAP were excluded from the analysis as
they were conﬁned to the EO group. Centers contributing cases for
this analysis included: the University of Louisville Medical Center
(Louisville, KY), Ohio State University Medical Center (Columbus,
OH), Henry Ford Health System (Detroit, MI), University of Miami/
Jackson Memorial Hospital (Miami, FL), and Summa Health System
(Akron, OH). The study was approved by the institutional review
board at each participating hospital, which all waived the need for
informed consent. University of Louisville was the coordinating
center and validated the quality of the data by checking for
discrepancies and inconsistencies. Upon validation, the case was
accepted for analysis. Patients included in this study were treated
during the period from November 2008 to July 2010.
2.2. Patient population and assessment
Adult patients (18 years of age) in participating ICUs were
eligible for inclusion if there was a clinical suspicion of evolvingpneumonia with new or progressive inﬁltrates on chest radiograph
and at least two of the following: new or increased cough or
sputum production, fever, hypothermia, leukocytosis, left shift,
leukopenia, deterioration of pulmonary function.11 We used the
American Thoracic Society (ATS)/Infectious Diseases Society of
America (IDSA) deﬁnitions for HAP, VAP, and HCAP.1 At the time of
diagnosis of pneumonia (day 0), we collected data on patient
demographic and baseline characteristics, severity of illness
including the Acute Physiology and Chronic Health Evaluation
(APACHE) II score12 and the Clinical Pulmonary Infection Score
(CPIS, also repeated on day 3),13 diagnostic procedures, and
treatment data including antibiotics received from day 0. Risk
factors for MDR pathogens (i.e., antibiotics within the prior 30
days; hospitalized for 5 days before antibiotics for HAP were
started; bronchiectasis; known family member with MDR patho-
gen; colonization with MRSA, Pseudomonas aeruginosa, Acineto-
bacter, and/or vancomycin-resistant Enterococcus (VRE);
hospitalized for >2 days within the prior 90 days; nursing home
or extended care facility; chronic dialysis within the prior 30 days;
home infusion therapy; home wound care; and immunosuppres-
sive disease and/or therapy) were collected. Patients were
considered at risk of MDR pathogens if they had one or more
factors present. Colonization was ascertained passively, based on
information included in the patient’s medical records at the time of
diagnosis. Patients were followed until hospital discharge, death,
or 28 days after pneumonia diagnosis, whichever occurred ﬁrst.
Laboratory values were collected during the index hospitalization.
Microbiology laboratories at each center provided semiquantita-
tive cultures of tracheal aspirates and either semiquantitative or
quantitative cultures of bronchoalveolar lavage specimens. All
culture results were reviewed at every site by the study
coordinator and principal investigator in order to classify identiﬁed
microorganisms as pathogenic or not.
2.3. Study deﬁnitions
All patients in this analysis met the ATS/IDSA deﬁnitions for
HAP or VAP and had a positive respiratory culture for MRSA.
Pneumonia occurring 5 days after the hospital admission was
deﬁned as LO pneumonia;1 all other patients were considered to
have EO pneumonia.
All-cause mortality was assessed at day 14 and day 28 after
pneumonia diagnosis.
2.4. Laboratory analysis of MRSA isolates
Initial identiﬁcation of MRSA isolates collected on day 0 and
in vitro antibiotic susceptibilities were determined using clinical
microbiology laboratory tests with automated susceptibility
testing methods at each participating center. Isolates were
shipped to the IMPACT-HAP microbiology reference laboratory
at Henry Ford Hospital for further evaluation. In vitro
susceptibilities to vancomycin were determined using the
standard Etest method, following the instructions provided by
the manufacturer (bioMe´rieux, Marcy l’Etoile, France). MRSA
isolates were further characterized by PFGE for USA typing.
Genomic DNA for PFGE was prepared, digested with SmaI (New
England BioLabs, Beverly, MA, USA), and run on a CHEF-DR III
(Bio-Rad Laboratories, Hercules, CA, USA) using a previously
described method.14 PFGE patterns were compared using
BioNumerics software (version 3.5; Applied Maths, Belgium).
Isolates were determined to be of the same PFGE strain group if
their SmaI restriction patterns were 80% similar using the Dice
coefﬁcient.15 Multiplex PCR ampliﬁcation was performed to
determine the staphylococcal cassette chromosome mec
(SCCmec) type (types I– V) using a previously described
Table 1
Characteristics of patients with methicillin-resistant Staphylococcus aureus (MRSA)






Male gender 26 (62%) 61 (66%) 0.6205
Age, mean (SD) 58 (19.2) 59.2 (17.7) 0.7329
APACHE II score, day 0, mean (SD) 20.4 (6.9) 20.3 (6.5) 0.9076
CPIS, day 0, mean (SD) 6.3 (1.8) 6.4 (1.8) 0.6265
CPIS, day 3, mean (SD) 6.8 (2.6) 6.4 (2.6) 0.3866
Risk factors of MDRO 32 (76%) 90 (98%) < 0.0001
Multilobar inﬁltrate 2 (33%) 21 (66%) 0.1375
Patients with severe sepsis 33 (79%) 66 (72%) 0.4036
Type of pneumonia 0.056
HAP 11 (26%) 40 (43%)
VAP 31 (74%) 52 (57%)
Underlying medical condition
Cardiac disease 16 (38%) 30 (33%) 0.5349
Renal disease 3 (7%) 16 (17%) 0.1147
Vascular disease 15 (36%) 33 (36%) 0.9861
Diabetes 10 (24%) 31 (34%) 0.2493
Respiratory disease 12 (29%) 24 (26%) 0.7634
Immunosuppressive disease and/or therapy
Cancer 3 (7%) 14 (15%) 0.1926
End-stage renal diseasea 0 (0%) 5 (5%) 0.1236
End-stage liver diseaseb 1 (2%) 3 (3%) 0.7738
End-stage lung diseasec 4 (10%) 11 (12%) 0.6786
Steroidsd 5 (12%) 5 (5%) 0.1925
Active chemotherapye 1 (2%) 1 (1%) 0.5666
Active radiotherapye 1 (2%) 0 (0%) 0.1374
Results are expressed as n (%), unless speciﬁed otherwise. APACHE II, Acute
Physiology and Chronic Health Evaluation II; CPIS, Clinical Pulmonary Infection
Score; HAP, hospital-acquired pneumonia; MDRO, Multi-drug resistant organism;
SD, standard deviation; VAP, ventilator-associated pneumonia.
a Clinical judgment of attending physician.
b Clinical or histological diagnosis of cirrhosis, or another form of chronic liver
disease.
c Chronic obstructive pulmonary disease with forced expiratory volume in 1 s
(FEV1) <30% or O2-dependent.
d Prednisone >10 mg/day for >7 days.
e Within last 30 days.
Table 2
Evaluation of the most common risk factors identiﬁed for multidrug-resistant
(MDR) pathogens in patients with methicillin-resistant Staphylococcus aureus
(MRSA) nosocomial pneumonia, by time of onset





Prior antibiotic use 20 (48%) 63 (69%) 0.0211
MRSA colonization 9 (21%) 23 (25%) 0.6528
VRE colonization 36 (86%) 61 (66%) 0.0197
Acinetobacter colonization 0 (0%) 3 (3%) 0.2366
Results are expressed as n (%). VRE, vancomycin-resistant Enterococcus.
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all isolates by PCR using agr group-speciﬁc primers.17 MRSA
strains were screened for the PVL toxin genes, lukS-PV and
lukF-PV, by PCR.18 Isolates were screened and tested for
vancomycin heteroresistance using the macrodilution Etest
method (bioMe´rieux, Durham, NC, USA), as previously described.19
2.5. Statistical analysis
Patients with EO MRSA nosocomial pneumonia were compared
against those patients with LO disease. Categorical variables were
compared using the Chi-square test or Fisher’s exact test, and
continuous variables were compared using the Student’s t-test and
the Mann–Whitney U-test, when appropriate. A similar approach
was followed when comparing laboratory characteristics of MRSA
isolates recovered from patients with EO and LO pneumonia.
p-Values of 0.05 were considered statistically signiﬁcant.
All analyses were performed using SAS software, version 9.2
(SAS Inc., Cary, NC, USA).
3. Results
3.1. Patient characteristics
A total of 134 ICU patients with MRSA nosocomial pneumonia
were identiﬁed in our database. Forty-two patients (31%) had EO
MRSA nosocomial pneumonia and 92 patients (69%) had LO MRSA
nosocomial pneumonia.
A greater frequency of risk factors for MDR pathogens was
found among patients in the LO group (Table 1). However, it is
important to note that risk factors for MDR bacterial pathogens
were documented in a majority of ICU patients with EO and LO
disease (76% and 98%, respectively). Patients with LO MRSA
pneumonia were more frequently diagnosed with HAP, although
the difference was not statistically signiﬁcant. We observed no
differences between the two groups in relation to gender, age, CPIS,
APACHE II score, severe sepsis diagnosis, or underlying medical
conditions. While multilobar inﬁltrates were more frequent among
patients in the LO group (66% vs. 33%), the difference did not reach
statistical signiﬁcance.
When we compared the presence of the most common risk
factors identiﬁed for MDR pathogens between the two groups
(Table 2), we observed that patients with LO MRSA nosocomial
pneumonia were more likely to have received antibiotics in the
prior 30 days, while EO MRSA nosocomial pneumonia patients
were more likely to be colonized with VRE.
3.2. Laboratory analysis of MRSA isolates
As depicted in Table 3, there were signiﬁcant differences in
MRSA USA subtypes between the EO and LO MRSA nosocomial
pneumonia study groups. USA100 strains (the traditional
healthcare-associated MRSA) were more frequent among patients
with LO MRSA pneumonia, while USA600 strains (rarely seen in
patients in the USA, associated with higher failure rates in patients
with bacteremia) were found predominantly among patients with
EO MRSA pneumonia.20 The USA300 subtype was found in 42% of
EO and in 38% of LO MRSA nosocomial pneumonia cases, however
this particular difference is not signiﬁcant (Chi-square standard-
ized residual = 0.20). Similarly, no signiﬁcant differences were
found between the two study groups in terms of the presence of
the PVL gene (p = 0.642), or SCCmec type IV (p = 0.365). We
observed more patients with a vancomycin MIC 2 mg/ml in the
LO group, though this difference did not reach statistical
signiﬁcance (p = 0.09).4. Discussion
Our results indicate that USA300 strains were isolated with
similar frequency in ICU patients with EO and LO MRSA nosocomial
pneumonia, a ﬁnding suggesting USA300 strains have become
established nosocomial pneumonia pathogens in our institutions.
Earlier studies had demonstrated EO and LO nosocomial
pneumonias to be caused by different groups of pathogens, with
MDR organisms predominantly associated with LO infections.21,22
Guidelines have thus recommended dividing nosocomial pneu-
monia into EO and LO pneumonia to help guide the selection of
appropriate empiric antimicrobial therapy.1 However, more recent
studies suggest MDR pathogens could be etiologic agents of
nosocomial pneumonia in patients with early onset of infection.
Giantsou et al. found no difference in the contribution of
potentially multiresistant pathogens (79% vs. 85%), P. aeruginosa
(42% vs. 47%), or MRSA (33% vs. 30%) between EO and LO VAP
Table 3
Characteristics of 134 methicillin-resistant Staphylococcus aureus (MRSA) strains
causing nosocomial pneumonia, by time of onset
Variable Early onset n = 42 Late onset n = 92 p-Value
USA strain 0.0091
USA100 15 (40%) 49 (60%)
USA200 2 (5%) 0 (0%)
USA300 16 (42%) 31 (37.8%)
USA600 5 (13%) 2 (2%)
PVL-positive PCR 14 (33%) 27 (29%) 0.6423
SCCmec type II 21 (88%) 53 (79%) 0.3652
SCCmec type IV 3 (13%) 14 (21%) 0.3652
agr type I 21 (50%) 35 (38%) 0.1219
agr type II 20 (48%) 57 (62%) 0.1219
agr type III 1 (2%) 0 (0%) 0.1219
Heteroresistance 5 (12%) 10 (11%) 0.8601
Vancomycin MIC 0.0907
<2 mg/ml 31 (74%) 52 (57%)
2 mg/ml 11 (26%) 40 (43%)
MIC, minimum inhibitory concentration; PCR, polymerase chain reaction; PVL,
Panton–Valentine leukocidin; SCC, staphylococcal cassette chromosome; agr,
accessory gene regulator.
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prospective cohort study, Verhamme and colleagues described 298
patients with ICU-acquired pneumonia, and pathogens potentially
resistant to multiple drugs including MRSA were isolated from 52%
of patients with EO pneumonia. Risk factors for the isolation of
these pathogens included older age and receipt of antibiotic
prophylaxis.24 In accordance with these observations we found a
signiﬁcant proportion of patients in both the EO and LO pneumonia
groups to have documented risk factors for MDR pathogens,
including previous receipt of antibiotics. As more patients with
complicated medical conditions are routinely cared for outside the
hospital, the distinction between EO and LO pneumonia may not be
as clinically relevant as in the past. Our data suggest that MDR
pathogens, MRSA in particular, should be an important consider-
ation in all patients with nosocomial pneumonia irrespective of
time of onset.
Likewise, the epidemiologic distinction between CA-MRSA and
HA-MRSA is blurring as MRSA strains of community origin are
increasingly identiﬁed causing healthcare-associated disease.
Klevens et al. at the US Centers for Disease Control and Prevention
(CDC) reported data from a multistate surveillance system for
invasive MRSA infections and found that 18–28% of patients with
healthcare-related risk factors had infection caused by a ‘commu-
nity-associated’ strain, primarily USA300.8 In a single-center
report, Seybold and colleagues at Grady Memorial Hospital, a
1000-bed, urban, public hospital in Atlanta, Georgia, USA, found
USA300 strains accounted for 28% of the MRSA healthcare-
associated bloodstream infections and 20% of nosocomial MRSA
bloodstream infections.25 Most recently, a multicenter ICU
epidemiology study in the USA reported 14% of patients admitted
to ICUs were colonized with a CA-MRSA genotype.26 Outside the
USA, 31.7% (39/123) of hospital-onset MRSA cases identiﬁed over 1
year in two urban hospitals in Vancouver, Canada were caused by
the USA300 strain, when previously only 6% of HA-MRSA infections
or colonizations reported from Canadian hospitals were attribut-
able to USA300 or USA400 strains.27 Our ﬁndings conﬁrm the prior
observations and expand them to a unique and speciﬁc group of
patients, ICU patients with nosocomial pneumonia. We believe this
is the ﬁrst study to speciﬁcally compare the genotype and
phenotype MRSA strain characteristics of EO vs. LO in ICU patients
with MRSA nosocomial pneumonia. In our large, multicenter
collection of MRSA nosocomial patients, we found a similar
distribution of USA300 MRSA strains in ICU patients irrespective of
EO or LO pneumonia. Ours was a well-characterized study
population with clinical and laboratory information available foranalysis. Furthermore, we explored the effect of a variety of
pathogen factors as well as host-related factors.
It is not clear why CA-MRSA has been successful in transitioning
from community into hospital settings, displacing HA-MRSA as a
cause of some healthcare-associated infections. Possible causes
include CA-MRSA as a more ‘ﬁt’ isolate than HA-MRSA.5 It has been
reported that CA-MRSA isolates carrying SCCmec type IV multiply
much faster than traditional HA-MRSA strains and have an
enhanced ecologic ﬁtness.28 The transition of CA-MRSA into
hospital settings will limit our ability to use clinical and
epidemiological risk factors when determining the risk for speciﬁc
MRSA infection types, in particular as molecular-based means of
classiﬁcation become more available.
The clinical implications of ﬁnding MRSA USA300 strains to
have become an established cause of nosocomial pneumonia in our
hospital intensive care units remain to be deﬁned. In vitro
susceptibilities to non-beta-lactam antibiotics for CA-MRSA strains
may differ from HA-MRSA strains, providing clinicians with more
available treatment options. USA300 strains have been reported in
the literature to be associated with a variety of virulence factors
(including the PVL gene), theoretically impacting the selection of
anti-MRSA therapy.28–30 Infections caused by MRSA strains
carrying the PVL gene have previously been reported to be
associated with poor clinical outcomes,29–33 but the deﬁnitive role
of PVL is unclear based on observations from more recent
studies.34–37 Yet the ﬁnding of a mixture of MRSA strains,
including HA-MRSA and USA300 isolates, as common pathogens
in both EO and LO nosocomial pneumonia implies a need for
clinicians to consider appropriate anti-MRSA therapy for all ICU
pneumonia cases regardless of the time of onset in relation to
hospital admission.
Although we did not ﬁnd a difference in the proportion of cases
of MRSA nosocomial pneumonia caused by USA300 strains
between EO and LO MRSA nosocomial pneumonia patients, we
did observe a trend of LO group patients being infected with CA-
MRSA with higher vancomycin MICs. The treatment implications
of this ﬁnding are unclear at present. Several studies have
demonstrated poor clinical outcomes associated with vancomycin
use in bacteremia as well as pneumonia patients infected with CA-
MRSA with high vancomycin MICs of 1.5 mg/ml or greater.38,39 This
suggests alternative therapies may be a better choice.
Our study has several limitations. First, the diagnosis of
pneumonia was based on clinical criteria despite the fact that
lower respiratory tract cultures were collected from all patients
before antibiotic therapy; using clinical criteria for the diagnosis of
HAP, VAP, and HCAP may lead to overdiagnosis. Second, the
etiologic diagnosis of MRSA pneumonia was based on respiratory
samples including sputum and tracheal aspirates, and the use of
samples other than bronchoalveolar lavage to characterize the
etiology of pneumonia may cause the inclusion of patients
colonized but not infected with MRSA. Third, IMPACT-HAP was
not a randomized controlled trial, and a major weakness of every
observational study of nonconsecutive patients is sampling error.
By including patients from different study sites, errors in the
selection of patients and data collection might have had less of an
inﬂuence on the results.40
A strength of our data is the enrollment of patients representing
different geographic areas in the USA, making our results more
generalizable. The IMPACT-HAP database includes a well-charac-
terized study population with detailed clinical and laboratory
information available for analysis. In addition, we used a central
reference laboratory for microbiology and molecular testing of the
available MRSA isolates.
In conclusion, the results of our study provide further evidence
of the continued migration of CA-MRSA into healthcare settings in
the USA, causing nosocomial infections and supplanting traditional
T.R. Pasquale et al. / International Journal of Infectious Diseases 17 (2013) e398–e403e402HA-MRSA strains as a cause of nosocomial pneumonia in the ICU.
The distinction of EO vs. LO ICU pneumonia is not as relevant as in
the past, as more patients with complicated medical conditions
cared for in outpatient settings are at risk of infection with MDR
pathogens, irrespective of the timing of the pneumonia. Clinicians
should consider starting anti-MRSA therapy empirically for all ICU
patients with pneumonia, regardless of the time of onset in relation
to hospital admission.
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